| ProductNum | picture | CAS No. | Name and description | Formula | Quick order | 
|---|---|---|---|---|---|
| CL3310 | 
                         | 
                    2728667-27-2 | 
                         Zongertinib (Synonyms: BI 1810631;BI 764532) 98+%  | 
                    C29H29N9O2 | |
| CL1991B | 
                         | 
                    2805804-54-8 | 
                         CP-547632 TFA 98+%  | 
                    C20H24BrF2N5O3S·C2HF3O2 | |
| CL2879A | 
                         | 
                    210644-62-5 | 
                         (Z)-Orantinib | (Z)-SU6668 | (Z)-TSU-68 98+%  | 
                    C18H18N2O3 | |
| CL2509 | 
                         | 
                    1013920-15-4 | 
                         Vorolanib (X-82,CM082) 98+%  | 
                    C23H26FN5O3 | |
| CL2507A | 
                         | 
                    1218779-75-9 | 
                         Apatinib Mesylate 98+%  | 
                    C24H23N5O · CH4O3S | |
| CL2507 | 
                         | 
                    811803-05-1 | 
                         Apatinib | Apatinib Free base | YN968D1| Rivoceranib 98+%  | 
                    C24H23N5O | |
| CL2424 | 
                         | 
                    557795-19-4 | 
                         Sunitinib | Sunitinib Base 99+%  | 
                    C22H27FN4O2 | |
| CLA1508 | 
                         | 
                    1607793-29-2 | 
                         Anti-Human VEGFAxANGPT2 (Faricimab; RG7716) 95+%  | 
                    — | |
| CLA1500 | 
                         | 
                    1969309-56-5 | 
                         Anti-Human Her2xHer3 (Zenocutuzumab; MCLA-128; PB4188; R040517) 95+%  | 
                    — | |
| CLA1339 | 
                         | 
                    1350624-75-7 | 
                         Margetuximab (Anti-ERBB2 / HER2 / CD340) 95+%  | 
                    — | |
| CLA1267 | 
                         | 
                    1024603-92-6 | 
                         Icrucumab (Anti-VEGFR1 / FLT1) 95+%  | 
                    — | |
| CLA1179 | 
                         | 
                    934216-54-3 | 
                         Alacizumab (Anti-VEGFR2 / KDR / CD309) 95+%  | 
                    — | |
| CL2214 | 
                         | 
                    215543-92-3 | 
                         (Z)-3-(4-methyl-2-((2-oxoindolin-3-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid. 98+%  | 
                    C17H16N2O3 | |
| CLA1033 | 
                         | 
                    1018448-65-1 | 
                         Ado-trastuzumab Emtansine (TDM-1) 95+%  | 
                    — | |
| CL1631 | 
                         | 
                    288383-20-0 | 
                         Cediranib | ADZ-2171 | NSC-732208 98+%  | 
                    C25H27FN4O3 | |
| CL1633 | 
                         | 
                    417716-92-8 | 
                         Lenvatinib | E7080 98+%  | 
                    C21H19ClN4O4 | |
| CL1636 | 
                         | 
                    444731-52-6 | 
                         Pazopanib | GW786034 99+%  | 
                    C21H23N7O2S | |
| CL1637 | 
                         | 
                    319460-85-0 | 
                         Axitinib | AG-013736 98+%  | 
                    C22H18N4OS | |
| CL1033 | 
                         | 
                    808118-40-3 | 
                         Roxadustat | FG-4592 98+%  | 
                    C19H16N2O5 | |
| CLA1025 | 
                         | 
                    380610-27-5 | 
                         Pertuzumab; 2C4 98+%  | 
                    — | |